CKD-MBD: an endless story

被引:10
作者
Brancaccio, Diego [1 ,2 ]
Cozzolino, Mario [2 ]
机构
[1] Renal Unit Simone Martini, Milan, Italy
[2] Univ Milan, Dept Med Surg & Dent, Milan, Italy
关键词
Calcium Sensing Receptor; Secondary hyperparathyroidism; Uremia; Vascular calcification; VDR; Vitamin D; CHRONIC KIDNEY-DISEASE; RENIN-ANGIOTENSIN SYSTEM; D-RECEPTOR ACTIVATION; VITAMIN-D; SECONDARY HYPERPARATHYROIDISM; VASCULAR CALCIFICATION; HEMODIALYSIS-PATIENTS; RENAL-FAILURE; DIABETIC-NEPHROPATHY; DIALYSIS PATIENTS;
D O I
10.5301/JN.2011.8310
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
100201 [内科学]; 100221 [泌尿外科学];
摘要
Renal failure is a growing problem that involves a large part of the population and has a great social impact, with often incapacitating complications, mainly related to mineral bone disorders (MBD) and cardiovascular diseases. Analysis of the recent scientific literature confirms that a large number of chronic kidney disease (CKD) patients develop an early derangement of the parameters of Ca-P metabolism in which phosphate homeostasis and a reduced endogenous synthesis of calcitriol play a critical role. Recent findings from several large observational studies have also suggested that the benefits of vitamin D receptor activators may extend beyond the traditional parathyroid hormone-lowering effect, and could result in direct cardiovascular and metabolic benefits. Treatment of secondary hyperparathyroidism has become even more complex with the arrival of the calcium-sensing receptor agonist cinacalcet hydrochloride and with the uncovering of novel mechanisms responsible for secondary hyperparathyroidism. The aim of this review is the analysis of some of the recent contributions in the field of CKD-MBD, to update the understanding of the pathogenetic mechanisms and possibly the most appropriate therapeutic approach in this field.
引用
收藏
页码:S42 / S48
页数:7
相关论文
共 38 条
[1]
Antiproteinuric effect of oral paricalcitol in chronic kidney disease [J].
Agarwal, R ;
Acharya, M ;
Tian, J ;
Hippensteel, RL ;
Melnick, JZ ;
Qiu, P ;
Williams, L ;
Batlle, D .
KIDNEY INTERNATIONAL, 2005, 68 (06) :2823-2828
[2]
Vitamin D in chronic kidney disease: A systemic role for selective vitamin D receptor activation [J].
Andress, DL .
KIDNEY INTERNATIONAL, 2006, 69 (01) :33-43
[3]
Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients [J].
Block, Geoffrey A. ;
Zaun, David ;
Smits, Gerard ;
Persky, Martha ;
Brillhart, Stephanie ;
Nieman, Kimberly ;
Liu, Jiannong ;
St Peter, Wendy L. .
KIDNEY INTERNATIONAL, 2010, 78 (06) :578-589
[4]
Brancaccio D, 2006, J NEPHROL, V19, P12
[5]
BRANCACCIO D, 2011, BLOOD PURIF IN PRESS
[6]
Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism [J].
Brancaccio, Diego ;
Bonimerz, Juergen ;
Coyne, Daniel .
DRUGS, 2007, 67 (14) :1981-1998
[7]
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[8]
Drug Insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease [J].
Brown, Alex J. ;
Slatopolsky, Eduardo .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (02) :134-144
[9]
Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients [J].
Caglar, Kayser ;
Yilmaz, Mahmut Ilker ;
Saglam, Mutlu ;
Cakir, Erdinc ;
Acikel, Cengizhan ;
Eyileten, Tayfun ;
Yenicesu, Mujdat ;
Oguz, Yusuf ;
Vural, Abdulgaffar ;
Carrero, Juan Jesus ;
Axelsson, Jonas ;
Lindholm, Bengt ;
Stenvinkel, Peter .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (01) :61-68
[10]
Capuano A, 2009, J NEPHROL, V22, P59